Drugs / H2NVAC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04144023 | Jun 2019 → Dec 2027 expected | ductal breast carcinoma in situ | Mayo Clinic | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H2NVAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04144023 ↗ |
| Modality | Vaccine | “multi-epitope HER2 peptide vaccine H2NVAC” NCT04144023 ↗ |